Talking Stocks Limelight Alpha

Editing genes to fix genetic mutations could revolutionize how we treat disease, but gene editing research is only in early stages, and plenty still needs to learned before we know it's safe for widespread use. 

In this episode of Limelight Alpha's Talking Stocks, 7Investing Lead Advisor, Maxx Chatsko, joins Todd Campbell to explains the pros and cons of gene editing. The duo discuss:


How gene editing, including CRISPR Cas, compares to RNAi therapies; 
What gene editing companies are furthest along in their research; 
What data is on tap from leading gene editing stocks, including Crispr Therapeutics, Editas Medicine, Caribou Biosciences, and Intellia Therapeutics, and
What could go wrong in gene editing drug development, including risks associated with double-strand breaks.

You can learn more about 7Investing here: https://7investing.com/subscribe/?referred_by_id=747

You can learn more about Limelight Alpha here: https://seekingalpha.com/author/limelight-alpha-management-partners/research

Follow Limelight Alpha on Twitter: @AlphaLimelight

Follow Maxx Chatsko on Twitter: @7MaxxChatsko




---

Support this podcast: https://podcasters.spotify.com/pod/show/limelight-alpha/support

The latest episode of Limelight Alpha’s Talking Stocks is packed with insight.

-What’s causing Pinterest’s shares to crash?

-Is Amazon in trouble?

-A 5G stock you can buy now

-Is Robinhood a buy?

-Is it safe to invest in China stocks?

-A slate of new stocks worth watching, and

-Todd’s latest stock buys.

A free trial to our stock idea research: https://seekingalpha.com/author/limelight-alpha-management-partners/research

If you enjoy our content, please subscribe on YouTube: https://www.youtube.com/c/TalkingStocksbyLimelightAlpha

Follow us on Twitter: https://twitter.com/AlphaLimelight 




---

Support this podcast: https://podcasters.spotify.com/pod/show/limelight-alpha/support

We're off this week, but we didn't want to leave you high and dry without any show at all! Enjoy a clip from our 2/10 episode (https://anchor.fm/limelight-alpha/episodes/Talking-Stocks---Bitcoin--Weed-Stocks--and-Buying-Strategy-eq7kfj) where Joe talks about his hesitancy (not anymore!) to buy stocks at all-time highs, and the valuable lesson he learned from buying cannabis ETF MJ near its peak. Our scoring model tends to reward stocks that are trading well above their moving averages - often at 52-week or all-time highs. This short is packed with tons of great buying and holding advice from Todd throughout. Enjoy!



Subscribe to our YouTube channel! https://www.youtube.com/c/TalkingStocksbyLimelightAlpha

Follow us on Twitter! https://twitter.com/AlphaLimelight

Follow Todd on Twitter: https://twitter.com/ebcapital

Subscribe to our stock picking service: https://seekingalpha.com/checkout?service_id=mp_46


---

Support this podcast: https://podcasters.spotify.com/pod/show/limelight-alpha/support

We're always working hard at Limelight Alpha to give you some great content and ideas - this week's episode is no exception! Here's our agenda:



- A silver lining of 6% inflation - 6% higher Social Security payouts! Todd explains how some of our older (but young at heart) listeners may benefit next year.

- Our investing style(s) - We have a discussion about where on the investing "spectrum" we fall: daytrader, swing/cyclical trader, or long-term holder.

- Then we dive into some of our trades over the past week. Todd was busy buying and selling!

- Finally, a back-and-forth of 8 high-scoring stocks for you to check out heading into next week.



If you enjoy our content, please subscribe here and on YouTube! We appreciate all of your support. https://www.youtube.com/c/TalkingStocksbyLimelightAlpha

Follow us on Twitter: https://twitter.com/AlphaLimelight


---

Support this podcast: https://podcasters.spotify.com/pod/show/limelight-alpha/support

A 4 day week doesn't mean there's any less to talk about! We've got another jam-packed show for you - below is our agenda:



- Amazon (AMZN)'s new CEO: A potential catalyst for a breakout long in the making?

- Generac (GNRC): an interesting seasonal play as we come into the height of hurricane season

- Didi (DIDI): A great example of why we avoid Chinese ADRs

- Todd and Joe's recent trades: We were busy adding and expanding positions this week, including DLTH, APPS, CRWD, and more

- Finally, 10 (+1 bonus!) high-scoring stocks to add to your watchlist



If you haven't already, consider signing up for our free trial: https://seekingalpha.com/author/limelight-alpha-management-partners/research

Subscribe to our YouTube channel! https://www.youtube.com/c/TalkingStocksbyLimelightAlpha

Follow us on Twitter! https://twitter.com/AlphaLimelight


---

Support this podcast: https://podcasters.spotify.com/pod/show/limelight-alpha/support

In this short from our 7/2/21 episode, we go deep into Robinhood's recent S-1 filing to extract all the info you need to invest (or not) in the future stock. There's no set IPO date yet (as of 7/7/21), but stay tuned: things happen fast. There were some surprising numbers in the S-1, including a billion-dollar loss in Q1 of this year. We'll tell you why that's not as alarming as it sounds.



Follow us on Twitter! https://twitter.com/AlphaLimelight

If you're subscribed to us on YouTube, thanks so much! If not, please check us out: https://www.youtube.com/c/TalkingStocksbyLimelightAlpha

You can also sign up for a free trial to our stock-picking tool: https://seekingalpha.com/author/limelight-alpha-management-partners/research


---

Support this podcast: https://podcasters.spotify.com/pod/show/limelight-alpha/support